Med24
metabolic-therapy 28. 10. 2026 • 2 min read • European heart journal (PubMed)

Cortisol in cardio-kidney-metabolic disease.

Despite guideline-directed therapy, many patients with cardio-kidney-metabolic (CKM) disease remain uncontrolled due to therapeutic inertia, adherence barriers, and underrecognized secondary causes. Hypercortisolism, ranging from mild autonomous cortisol secretion (MACS) to overt Cushing syndrome, is an increasingly...

Cortisol in cardio-kidney-metabolic disease.

Cardio-kidney-metabolic (CKM) disease often remains uncontrolled despite standard treatment, influenced by factors like adherence and unrecognized secondary causes. Hypercortisolism, encompassing mild autonomous cortisol secretion (MACS) to Cushing syndrome, is increasingly recognized as a contributing factor.

Hypercortisolism and Associated Risks

Elevated cortisol levels are linked to a significantly higher risk of cardiovascular death and increased prevalence of hypertension and type 2 diabetes mellitus (T2DM), alongside kidney impairment. This excess promotes insulin resistance, increased glucose production, β-cell dysfunction, sodium retention, and vascular changes, exacerbating CKM complications. Studies indicate hypercortisolism is more common than previously thought, observed in approximately 24% of patients with difficult-to-control T2DM and 27% in those with resistant hypertension. The overnight 1 mg dexamethasone suppression test is the preferred diagnostic method.

Sponsored content

Diagnostic and Treatment Strategies

Treatment strategies involve adrenal steroidogenesis inhibitors, glucocorticoid receptor antagonists, and pituitary-directed therapies, with surgery being the initial approach for surgically correctable conditions. This review details the connection between cortisol excess and CKM dysfunction, emphasizing the need for clinical trials, standardized diagnostic criteria, and assays to incorporate cortisol-targeted therapies into management. The aim is to address residual CKM risk and provide a practical guide for cardiologists in managing this potentially reversible contributor to poor CKM control.

Original Scientific Source
European heart journal (PubMed)
View Original Source
Medical Disclaimer All calculations, recommendations, and interpretations provided by this tool are for informational and educational purposes only. They do not substitute professional medical advice, diagnosis, or treatment. Always consult your physician regarding any health concerns.

Recommended Medical News

All news →
Nanotechnology-Driven 18F-FDG Imaging to Understand the Change in Insulin Sensitivity: Current Evidence, Methodological Gaps, and Translational Challenges.
metabolic-therapy

Nanotechnology-Driven 18F-FDG Imaging to Understand the Change in Insulin Sensitivity: Current Evidence, Methodological Gaps, and Translational Challenges.

Insulin resistance is an important metabolic derangement contributing to the pathogenesis of type 2 diabetes, obesity, metabolic syndrome, and other chronic diseases, underlining the requirement for techniques that enable in vivo analysis of tissue-specific glucose metabolism. 18F-fluorodeoxyglucose positron emission...

10. 11. 2026 Read article →
Cardiometabolic Abnormalities among Normal-Weight Adults: Prevalence and Associated Sociodemographic and Lifestyle Factors in a Large Spanish Cohort.
metabolic-therapy

Cardiometabolic Abnormalities among Normal-Weight Adults: Prevalence and Associated Sociodemographic and Lifestyle Factors in a Large Spanish Cohort.

BACKGROUND: Although body mass index (BMI) is widely used to assess obesity-related health risks, it may fail to detect individuals with normal weight who present with significant cardiometabolic abnormalities. This phenotype, often overlooked in clinical practice, is associated with increased risk of cardiovascular...

30. 10. 2026 Read article →
Advertisement